Publication | Open Access

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Independent Reactive CentersDrug TargetingMedicineReceptor Tyrosine KinaseDifferent Cysteine ResiduesAnti-cancer AgentQuinazoline-based InhibitorsPharmacologyRadiation OncologyNovel TherapyDrug Discovery